Przemyslaw W. Twardowski, MD
While there has been some progress with treating prostate cancer, how to prevent the progression of metastatic prostate cancer is still unclear, according to Przemyslaw W. Twardowski, MD.
on Genitourinary Cancers, Twardowski, professor of medical oncology at John Wayne Cancer Institute (JWCI), discussed a variety of factors to consider when treating patients with prostate cancer.
OncLive: What are some factors that you take into consideration when choosing which androgen-receptor (AR) targeted therapy is best for patients with prostate cancer?
That’s a great question and not easy to answer because we don't really have any laboratory molecular biomarkers that would guide us. I sometimes joke that, in many ways, for me, in the regular practice setting, the choice between the key second-generation androgen pathway inhibitors, such as abiraterone acetate and enzalutamide, is almost like flipping a coin, essentially. There are very subtle nuanced clinical factors that may influence one agent over the other.
... to read the full story